1. Home
  2. Analysis

Hyperammonaemia and drugs of ingredients of olmesartan medoxomil (a real world drug study)


Summary:

Hyperammonaemia is found among people who take drugs with ingredients of olmesartan medoxomil, especially for people who are female, 60+ old , have been taking the drugs for 1 - 2 years. This phase IV clinical study is created by eHealthMe based on reports of 57,543 people who have side effects when taking drugs with ingredients of olmesartan medoxomil from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Benicar, Olmesartan medoxomil, Olmetec.

On Jul, 03, 2026

57,543 people reported to have side effects when taking drugs with ingredients of olmesartan medoxomil.
Among them, 12 people (0.02%) have Hyperammonaemia

What is Hyperammonaemia?

Hyperammonaemia is found to be associated with 400 drugs and 560 conditions by eHealthMe. Check the latest studies of Hyperammonaemia.

Number of reports submitted per year:

Could drugs with ingredients of olmesartan medoxomil cause Hyperammonaemia?

Time on drugs with ingredients of olmesartan medoxomil when people have Hyperammonaemia *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 33.33 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 66.67 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Hyperammonaemia when taking drugs with ingredients of olmesartan medoxomil *:

  • female: 75 %
  • male: 25 %

Age of people who have Hyperammonaemia when taking drugs with ingredients of olmesartan medoxomil *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Conditions people have *:

You may use this to check any potential undetected conditions.

  1. Constipation: 4 people, 33.33%
  2. Breast Cancer: 4 people, 33.33%
  3. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 25.00%
  4. Asthma: 3 people, 25.00%
  5. Type 2 Diabetes: 2 people, 16.67%
  6. Hyperuricaemia (level of uric acid in the blood that is abnormally high): 1 person, 8.33%
  7. Dyslipidaemia (abnormal amount of lipids): 1 person, 8.33%
  8. Diabetes: 1 person, 8.33%
  9. Dementia Alzheimer's Type (loss of mental ability with alzheimer's symptom): 1 person, 8.33%
  10. Colon Cancer: 1 person, 8.33%

Other drugs people take *:

You may use this to check any potential interacting drugs.

  1. Lantus: 4 people, 33.33%
  2. Arimidex: 4 people, 33.33%
  3. Fish Oil: 3 people, 25.00%
  4. Cascara Sagrada: 2 people, 16.67%
  5. Zetia: 1 person, 8.33%
  6. Tresiba: 1 person, 8.33%
  7. Sinemet: 1 person, 8.33%
  8. Levoleucovorin Calcium: 1 person, 8.33%
  9. Eliquis: 1 person, 8.33%
  10. Aricept: 1 person, 8.33%

Other side effects people have besides Hyperammonaemia *:

You may use this to check any potential undetected side effects.

  1. Hepatitis Acute: 4 people, 33.33%
  2. Thrombocytopenia (decrease of platelets in blood): 3 people, 25.00%
  3. Leukocytosis (increased white blood cells): 3 people, 25.00%
  4. Arrhythmias (irregular heartbeat): 3 people, 25.00%
  5. Atelectasis (partial or complete collapse of the lung): 3 people, 25.00%
  6. Celiac Disease - Sprue (a disease of the small intestine): 3 people, 25.00%
  7. Chills (felling of cold): 3 people, 25.00%
  8. Depression: 3 people, 25.00%
  9. Gait Disturbance: 3 people, 25.00%
  10. Gastric Polyps (abnormal growth of stomach tissue projecting from a mucous membrane): 3 people, 25.00%

* Approximation only. Some reports may have incomplete information.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Drugs with ingredients of olmesartan medoxomil, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on olmesartan medoxomil. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.